General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characterizing such behavior is described and explored through computer simulations and applications to several therapeutic agents. Simulations show that model predicted plasma concentration vs. time profiles are expected to be polyexponential with steeper distribution phases for lower doses and similar terminal disposition phases. Noncompartmental parameters always show apparent Vss and CL(D) decreasing with dose, but apparent clearance decreases only when the binding process produces drug elimination. The proposed model well captured the time-course of drug concentrations for the aldose reductase inhibitor imirestat, the endothelin receptor antagonist bosentan, and recombinant human interferon-beta 1a. This type of model has a mechanistic basis and considerable utility for fully describing the kinetics for various doses of relevant drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More importantly, target-mediated drug disposition (TMDD) introduces a saturable, dose- and concentration-dependent component of clearance that no power-law regression can capture.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“At low concentrations, target-mediated clearance can dominate; at high concentrations, the target is saturated and linear, FcRn-mediated elimination dominates [47,50].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“A practical constraint in biologics first-in-human modelling is that not all of these disposition parameters can be identified simultaneously. FcRn-mediated linear clearance and central volume of distribution generally scale reliably from non-human primate data and can be estimated with reasonable confidence, whereas TMDD parameters such as target baseline concentration, target turnover, and”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“For biologics in particular, this also recognizes that not all parameters are simultaneously identifiable: FcRn-mediated linear clearance and central volume can be carried from non-human primate data, whereas poorly identifiable TMDD parameters are fixed to in vitro or literature values rather than estimated [50,51] (Section 4.5).”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
Citations
Cites
Gibaldi, M., & Perrier, D. (1982) · CRC Press eBooks · doi:10.1201/b14095 · Cited by 4,093
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Pestka, S., Langer, J. A., Zoon, K. C., & Samuel, C. E. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.003455 · Cited by 1,825
Protein Sorting by Transport Vesicles
Rothman, J. E., & Wieland, F. T. (1996) · Science · doi:10.1126/science.272.5259.227 · Cited by 1,153
Operational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society of London. Series B. Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 951
Comparison of four basic models of indirect pharmacodynamic responses
Dayneka, N. L., Garg, V., & Jusko, W. J. (1993) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061691 · Cited by 821
Self-citationClozel, M., Breu, V, Gray, G. A., Kalina, B., Löffler, B. M., Burri, K., Cassal, J. M., Hirth, G., Müller, M., & Neidhart, W. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22357-6 · Cited by 661
Recycling receptors: the round-trip itinerary of migrant membrane proteins
Brown, M. S., Anderson, R. G. W., & Goldstein, J. L. (1983) · Cell · doi:10.1016/0092-8674(83)90052-1 · Cited by 587
Gianni, L., Kearns, C. M., Giani, A., Capri, G., Viganó, L., Lacatelli, A., Bonadonna, G., & Egorin, M. J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.180 · Cited by 553
Phase I study of recombinant tumor necrosis factor in cancer patients.
Blick, M. B., Sherwin, S. A., Rosenblum, M. G., & Gutterman, J. U. (1987) · PubMed · Cited by 426
Research works printed but not linked: 3
- D. Z. D'Argenio and A. Schumitzky. ADAPT II user's guide. Biomedical Simulations Resource, Los Angeles (1997).
- W. J. Jusko. Guidelines for collection and analysis of pharmacokinetic data. In W. E. Evans, J. J. Schentag, and W. J. Jusko (eds.), Applied Pharmacokinetics, Applied Therapeutics, Inc., Vancouver, 1992, Ch. 2.
- J. G. Wagner. A new generalized nonlinear pharmacokinetic model and its implications. In J. G. Wagner (ed.), Biopharmaceutics and Relevant Pharmacokinetics, Drug Intelligence Publications, Hamilton, 1971, pp. 302–317.
Cited by
Items 301–400 of 612
Nanoparticle Pharmacokinetics and Toxicokinetics
Singh, A. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801406-6.00006-6 · Cited by 18
Park, W., Han, S., Lee, J.-T., Hong, T., Won, J., Lim, Y., Lee, K., Byun, H. Y., & Yim, D. (2016) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12675 · Cited by 15
Wei, X., Gibiansky, L. V., Wang, Y., Fuh, F. K., Erickson, R., O’Byrne, S., & Tang, M. T. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1031 · Cited by 14
Pivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Development
AHMED, M. A., Patel, C. A., Drezner, N. L., Helms, W. S., Tan, W., & Stypinski, D. (2019) · Clinical and Translational Science · doi:10.1111/cts.12703 · Cited by 14
Fundamentals Applications of Controlled Release Drug Delivery
Jan, M. S., Alam, W., & Shabnam, M. (2023) · Pharmaceutical science. · doi:10.5772/intechopen.113283 · Cited by 14
Lau, Y. Y., Ma, P., Gibiansky, L. V., Komorowski, R., Wang, J., Wang, G., Yan, H., Véniant, M. M., & Kakkar, T. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9150-z · Cited by 14
AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies
Stein, A., & Ramakrishna, R. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12169 · Cited by 14
Byun, J. H., & Jung, I. H. (2019) · Applied Mathematical Modelling · doi:10.1016/j.apm.2019.10.037 · Cited by 14
Development of Biosimilars—Pharmacokinetic and Pharmacodynamic Considerations
Wang, Y., & Chow, A. T. (2009) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400903280357 · Cited by 14
Chimalakonda, A., Yadav, R., & Marathe, P. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9477-3 · Cited by 14
Rodríguez‐Vera, L., Ramos, M., Fernández-Sánchez, E. M., Soriano, J. L., Guitart, C. P., Hernández, G. C., Jacobo‐Cabral, C. O., Suárez, N. D. C., & Colom, H. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.496 · Cited by 16
Elkomy, M. H., Widness, J. A., & Veng‐Pedersen, P. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.036236 · Cited by 14
Lü, D., Yadav, R., Holder, P. G., Chiang, E. Y., Sanjabi, S., Poon, V., Bernett, M. J., Varma, R., Liu, K., Leung, I., et al. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106450 · Cited by 13
Biliouris, K., Nestorov, I. A., Naik, H., Dai, D., Xiao, G., Wang, Q. L., Pellerin, A., Rabah, D., Lesko, L. J., & Trame, M. N. (2018) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-018-9609-6 · Cited by 15
Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer
Papachristos, A., Karatza, E., Kalofonos, H. P., & Sivolapenko, G. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113753 · Cited by 13
Ternant, D., Tilly, O. L., Picon, L., Moussata, D., Passot, C., Bejan‐Angoulvant, T., Desvignes, C., Mulleman, D., Goupille, P., & Paintaud, G. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111821 · Cited by 13
Johansson, C.-C., Gennemark, P., Artursson, P., Äbelö, A., Ashton, M., & Jansson‐Löfmark, R. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9293-x · Cited by 14
Gibiansky, L. V., & Gibiansky, E. (2017) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-017-9533-1 · Cited by 13
Ahmed, S., Ellis, M., Li, H., Pallucchini, L., & Stein, A. M. (2019) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-019-09638-3 · Cited by 13
An, G., & Katz, D. A. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2185 · Cited by 13
Stahl, A., Azuma, N., Wu, W., Lepore, D., Sukgen, E. A., Nakanishi, H., Mazela, J. L., Leal, S., Pieper, A., Schlief, S., et al. (2024) · Eye · doi:10.1038/s41433-023-02919-9 · Cited by 12
A Comprehensive Review of Novel Drug–Disease Models in Diabetes Drug Development
Gaitonde, P., Garhyan, P., Link, C., Chien, J. Y., Trame, M. N., & Schmidt, S. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0359-y · Cited by 14
Ngo, L. T., Oh, J., Kim, A., Back, H., Kang, W.-H., Chae, J., Yun, H., & Lee, H. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12555 · Cited by 13
Monoclonal Antibodies: Interspecies Scaling With Minimal Preclinical Information
Han, C., & Zhou, H. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.1 · Cited by 12
Zhang, T., Ma, J., Durbin, K. R., Montavon, T. J., Lacy, S. E., Jenkins, G. J., Doktor, S. Z., & Kalvass, J. C. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0352-8 · Cited by 13
Wu, N., Hammock, B. D., Lee, K. S. S., & An, G. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.265330 · Cited by 12
Nakada, T., & Mager, D. E. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15845 · Cited by 13
Self-citationYadav, R., Sukumaran, S., Zabka, T. S., Li, J., Oldendorp, A., Morrow, G. R., Reyes, A. E., Cheu, M., Li, J. L., Wallin, J. J., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050970 · Cited by 13
Quality Assessment of Bioanalytical Quantification of Monoclonal Antibody Drugs
Lee, J. W., & Kelley, M. M. (2011) · Therapeutic Delivery · doi:10.4155/tde.10.99 · Cited by 12
Population PK‐PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197
Buck, S., Hueber, W., Vitaliti, A., Straube, F., Emotte, C., Bruin, G. J. M., & Woessner, R. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12037 · Cited by 12
Zhu, P., Sy, S. K. B., & Skerjanec, A. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0196-7 · Cited by 13
Ait‐Oudhia, S., Scherrmann, J., & Krzyżański, W. (2010) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.712 · Cited by 12
Slow Invariant Manifolds of Fast-Slow Systems of ODEs with Physics-Informed Neural Networks
Patsatzis, D. G., Russo, L., & Siettos, C. I. (2024) · SIAM Journal on Applied Dynamical Systems · doi:10.1137/24m1656402 · Cited by 12
Straube, R. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70048 · Cited by 11
Bioanalytical Considerations in The Comparability Assessment of Biotherapeutics
Lee, J. W., Wang, Y., Moxness, M. S., & Desilva, B. S. (2011) · Bioanalysis · doi:10.4155/bio.11.25 · Cited by 11
Almquist, J. O., Penney, M., Pehrsson, S., Sandinge, A., Janefeldt, A., Maqbool, S., Madalli, S., Goodman, J., Nylander, S., & Gennemark, P. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12089 · Cited by 11
Shah, D. K., & Balthasar, J. P. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-013-9346-9 · Cited by 11
Geometric singular perturbation analysis of a dynamical target mediated drug disposition model
Kristiansen, K. U. (2019) · Journal of Mathematical Biology · doi:10.1007/s00285-019-01354-3 · Cited by 11
D’Cunha, R., Schmidt, R. L., Widness, J. A., Mock, D. M., Yan, X., Cress, G. A., Kuruvilla, D., Veng‐Pedersen, P., & An, G. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105013 · Cited by 11
Wu, N., & An, G. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00481-w · Cited by 11
Impact of enzyme turnover on the dynamics of the Michaelis–Menten model
Peletier, L. A., & Gabrielsson, J. (2022) · Mathematical Biosciences · doi:10.1016/j.mbs.2022.108795 · Cited by 11
At the bench: the key role of PK–PD modelling in enabling the early discovery of biologic therapies
Penney, M., & Agoram, B. M. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12225 · Cited by 11
Elkomy, M. H., Schmidt, R. L., Widness, J. A., & Veng‐Pedersen, P. (2011) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.757 · Cited by 11
Bernstein, S. H., Jusko, W. J., Krzyżański, W., Nichol, J. L., & Wetzler, M. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/00912700222011553 · Cited by 11
Self-citationJansson‐Löfmark, R., Na‐Bangchang, K., Björkman, S. E., Doua, F., & Ashton, M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04101-14 · Cited by 11
Sternebring, O., Alifrangis, L. H., Christensen, T. F., Ji, H., Hegelund, A. C., & Högerkorp, C. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21277 · Cited by 11
Tiwari, A., Luo, H., Chen, X., Singh, P., Bhattacharya, I., Jasper, P., Tolsma, J., Jones, H., Zutshi, A., & Abraham, A. K. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12126 · Cited by 12
Sugimoto, H., Chen, S. E., & Qian, M. G. (2020) · Molecules · doi:10.3390/molecules25030535 · Cited by 11
Hartmann, S., Biliouris, K., Naik, H., Rabah, D., Stevenson, L. F., Shen, C., Nestorov, I. A., Lesko, L. J., & Trame, M. N. (2020) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-020-09688-y · Cited by 11
Benson, N., van der Graaf, P. H., & Peletier, L. A. (2012) · Journal of Mathematical Biology · doi:10.1007/s00285-012-0620-z · Cited by 11
Baek, M., & Weiß, M. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078345 · Cited by 11
Bulitta, J. B., & Holford, N. H. G. (2008) · Wiley eBooks · doi:10.1002/9780471462422.eoct340 · Cited by 11
Wang, Z., Jin, Y., Shen, Q., Lang, Z., Liu, R., Di, X., Xiang, L., Zhang, G., Wang, Y., Wang, Y., et al. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.106104 · Cited by 10
Methamphetamine detection using nanoparticle-based biosensors: A comprehensive review
Lal, K., Noble, F. K., & Arif, K. M. (2022) · Sensing and Bio-Sensing Research · doi:10.1016/j.sbsr.2022.100538 · Cited by 12
Nishimura, J., Soubret, A., Arase, N., Buatois, S., Hotta, M., Charoin, J., Ito, Y., Sreckovic, S., Takamori, H., Bucher, C. M., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2851 · Cited by 10
A Critical Analysis of the FDA’s Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity
Niazi, S. K. (2023) · Pharmaceuticals · doi:10.3390/ph16111556 · Cited by 13
Byun, J. H., Jeon, H., Yun, H., & Kim, J. K. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012066 · Cited by 10
Local depletion of large molecule drugs due to target binding in tissue interstitial space
Zasedateleva, T., Schaller, S., de Lange, E. C. M., & de Witte, W. E. A. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13262 · Cited by 11
Qin, A., Shimoda, K., Suo, S., Fu, R., Kirito, K., Wu, D., Liao, J., Chen, H., Wu, L., Su, X., et al. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70109 · Cited by 10
Tian, Y., Enioutina, E. Y., Brunner, H. I., Vinks, A. A. T. M. M., & Sherwin, C. M. T. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0426-z · Cited by 10
Chen, X., DuBois, D. C., Almon, R. R., & Jusko, W. J. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074799 · Cited by 10
Self-citationLiu, S., & Shah, D. K. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000460 · Cited by 12
Reijers, J. A. A., van Donge, T., Schepers, F. M. L., Burggraaf, J., & Stevens, J. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2101-6 · Cited by 10
Nicolas, X., Djebli, N., Rauch, C., Brunet, A., Hurbin, F., Martinez, J.-M., & Fabre, D. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0670-5 · Cited by 10
Park, S., Yoon, S. S., Lee, J. H., Park, J. S., Jang, J. H., & Lee, J. W. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1889-7 · Cited by 10
Impact of altered endogenous IgG on unspecific mAb clearance
Fuhrmann, S., Kloft, C., & Huisinga, W. (2017) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-017-9524-2 · Cited by 11
Asymptotic analysis of a TMDD model: when a reaction contributes to the destruction of its product
Michalaki, L. I., & Goussis, D. A. (2018) · Journal of Mathematical Biology · doi:10.1007/s00285-018-1234-x · Cited by 10
Wu, X., Nekka, F., & Li, J. (2019) · Bulletin of Mathematical Biology · doi:10.1007/s11538-019-00651-8 · Cited by 10
Ternant, D., Pfister, M., Tilly, O. L., Mulleman, D., Picon, L., Willot, S., Passot, C., Bejan‐Angoulvant, T., Lecomte, T., Paintaud, G., et al. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01057-3 · Cited by 10
Half-life extension of therapeutics: Applications and mechanisms
Pathivada, K., & Glassman, P. M. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103724 · Cited by 9
Cheng, S., Flora, D. R., Rettie, A. E., Brundage, R. C., & Tracy, T. S. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.001048 · Cited by 9
Pharmacokinetics and Toxicity Considerations for Antibody–drug Conjugates: An Overview
Hejmady, S., Pradhan, R., Kumari, S., Pandey, M., Dubey, S. K., & Taliyan, R. (2023) · Bioanalysis · doi:10.4155/bio-2023-0104 · Cited by 9
Sepp, A., & Muliaditan, M. (2024) · mAbs · doi:10.1080/19420862.2024.2324485 · Cited by 9
Page, K. R., Mezzalana, E., MacDonald, A. J., Zamuner, S., Nicolao, G. D., & van Maurik, A. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.224899 · Cited by 9
Salgado, E., & Cao, Y. (2020) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2021006 · Cited by 9
Lassman, M. E., Chappell, D. L., McAvoy, T., Cheng, A., de Alwis, D. P., Pruitt, S. K., Laterza, O., Li, C. H., Stoch, A., & Mayawala, K. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2129 · Cited by 9
Which factors matter the most? Revisiting and dissecting antibody therapeutic doses
Tang, Y., Li, X., & Cao, Y. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.04.022 · Cited by 9
Marcantonio, D. H., Matteson, A., Presler, M., Burke, J. M., Hagen, D., Hua, F., & Apgar, J. F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.864768 · Cited by 9
Takahashi, T., Teramoto, M., Matsumoto, K., Jaber, M. M., Tamaki, H., Ikegame, K., Yoshihara, S., & Kaida, K. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01252-4 · Cited by 9
Yamaoka, K., & Takakura, Y. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.397 · Cited by 9
Ahn, L. Y., Shin, K.-H., Lim, K. S., Kim, T.-E., Jeon, H., Yoon, S. H., Cho, J., Shin, S. G., Jang, I., & Yu, K. S. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0130-9 · Cited by 9
Ait‐Oudhia, S., Vermeulen, A., & Krzyżański, W. (2010) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.733 · Cited by 9
Dose correction for the Michaelis–Menten approximation of the target-mediated drug disposition model
Yan, X., & Krzyżański, W. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-011-9233-1 · Cited by 9
Bulitta, J. B., & Holford, N. H. G. (2014) · Wiley eBooks · doi:10.1002/9781118445112.stat06889 · Cited by 9
Application of Modeling and Simulation in the Development of Protein Drugs
Roskos, L. K., Ren, S., & Robbie, G. J. (2010) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4419-7415-0_17 · Cited by 8
An SIS network model with flow driven infection rates
Punzo, G. (2022) · Automatica · doi:10.1016/j.automatica.2021.110107 · Cited by 8
Factors affecting peptide and protein absorption, metabolism, and excretion
Ashique, S., Garg, A., Sirohi, E., Kumar, S., Mohanalakshmi, S., & Mishra, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18925-8.00004-0 · Cited by 9
Shin, K.-H., Kim, T., Lim, K. S., Yoon, S.-H., Cho, J., Kim, S.-E., Park, K.-M., Shin, S., Jang, I., & Yu, K. (2013) · BioDrugs · doi:10.1007/s40259-013-0010-0 · Cited by 8
New Equilibrium Models of Drug-Receptor Interactions Derived from Target-Mediated Drug Disposition
Peletier, L. A., & Gabrielsson, J. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0221-x · Cited by 8
Jamois, C., Gibiansky, E., Gibiansky, L. V., Buchheit, V., Sahin, D., Cartron, G., Marcus, R. E., Hiddemann, W., Seymour, J. F., Strefford, J. C., et al. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13920 · Cited by 8
Ahlberg, J., Giragossian, C., Li, H., Myzithras, M., Raymond, E., Caviness, G. O., Grimaldi, C. M., Brown, S.-E., Perez, R., Yang, D., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1615345 · Cited by 8
Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists
Volz, A., Dingemanse, J., Krause, A., & Lehr, T. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2723-3 · Cited by 8
Zhao, Y., Dai, X., Liu, J., Li, X., Yang, J., Sun, H., Wu, P., Shen, J., Lu, J.-P., Xie, H., et al. (2012) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2012.06.001 · Cited by 8
Wang, L., Qiang, W., & Cheng, Z. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.12.021 · Cited by 8
Deng, Y., Hu, L., Qiang, W., Cheng, Z., Wang, L., & Wang, X. (2018) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12924 · Cited by 8
Tian, X., Yu, Y., Neeli, H., & Jappar, D. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3513 · Cited by 7
Clearance of rFVIIa and NN1731 after intravenous administration to Beagle dogs
Agersø, H., Kristensen, N. R., Østergaard, H., Karpf, D. M., Hermit, M. B., Pelzer, H., Petersen, L. C., & Ezban, M. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.02.013 · Cited by 7
A cell-level model of pharmacodynamics-mediated drug disposition
Krzyżański, W., Harrold, J. M., Wu, L. S., & Ruixo, J. J. P. (2016) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9491-z · Cited by 7
Byun, J. H., & Jung, I. H. (2018) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2018.01.028 · Cited by 7
MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues
Lavezzi, S. M., Mezzalana, E., Zamuner, S., Nicolao, G. D., Ma, P., & Simeoni, M. (2018) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-018-9608-7 · Cited by 7
Metadata
- Authors
- Mager, D. E., & Jusko, W. J.
- Affiliations
- University at Buffalo, State University of New York (US)
- Venue
- Journal of Pharmacokinetics and Pharmacodynamics
- Published
- 2001-12
- Volume
- 28
- Issue
- 6
- Pages
- 507-532
- ISSN
- 1567-567X (ISSN-L)
- 1573-8744
- OpenAlex
- W28215347
- Cited by
- 605
- References
- 40
- Citations by year
- 2026: 40 · 2025: 27 · 2024: 30 · 2023: 32 · 2022: 31 · 2021: 31 · 2020: 40 · 2019: 37 · 2018: 28 · 2017: 31 · 2016: 32 · 2015: 41 · 2014: 31 · 2013: 36 · 2012: 32
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Journal of Pharmacokinetics and Pharmacodynamics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM 57980, R01GM057980)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- target-mediated drug disposition, nonlinear pharmacokinetics, receptor-mediated endocytosis, pharmacokinetic modeling, dose-dependent clearance, drug elimination, bosentan, interferon beta-1a, enzyme inhibitors, receptor antagonists
- MeSH terms
- Bosentan, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Fluorenes, Humans, Hydantoins, Male, Models, Chemical, Pharmacokinetics, Sulfonamides, Drug Delivery Systems, Interferon-beta, Nonlinear Dynamics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.